Parexel has acquired Vitrana, a provider of an Artificial Intelligence (AI)-enabled, end-to-end pharmacovigilance (PV) technology platform. Financial terms were not disclosed.

The acquisition further expands Parexel's technology capabilities to better serve customers. It provides an integrated PV platform that leverages intelligent automation and AI to accelerate end-to-end patient safety and PV processes, deliver first-time quality and enhance compliance. The technology platform is system-agnostic and integrates with any safety database–allowing customers to deploy the capabilities that best fit their needs–improving accuracy, cycle times and delivering measurable and sustainable efficiencies. The acquisition underscores Parexel’s continued investment in AI-enabled solutions across clinical development from regulatory submissions to trial execution and now patient safety.

Sanjay Vyas, President of Patient Safety Services and Clinical Logistics, and Managing Director, India, Parexel, said, "With Vitrana, we can now offer customers a single partner for both PV technology and services–and that changes what we can deliver for them. Our customers will benefit from best-in-class, technology-enabled PV services that handle growing regulatory volume and complexity, enhance compliance, streamline workflows, and enable experts to focus on what matters most: product and patient safety. This acquisition aligns with Parexel’s commitment to operational excellence and enables us to deliver year-over-year operational and efficiency gains to customers while maintaining the highest standards of quality delivery across patient safety operations."

The acquisition delivers tangible benefits throughout the clinical trial ecosystem and post-approval market. Responding to customers’ increasing preferences for a fully integrated model for PV operations, Parexel now offers one partner responsible for technology and services. In addition, this integrated model provides customers with better pricing flexibility, faster issue resolution, streamlined vendor management, and a unified roadmap for innovation and performance. The acquisition also reduces the burden on investigative sites through improved Electronic Data Capture (EDC)-to-safety integration and streamlined Serious Adverse Event (SAE) reconciliation, while patients benefit from easier reporting through intuitive, digital adverse event reporting channels.

Mohit Gupta, President and CEO, Vitrana, "We're thrilled to join Parexel and further scale our proven technology and our experienced team as we strengthen pharmacovigilance solutions. Together, we can offer improved efficiency, quality and compliance for our customers worldwide."

Vitrana’s team and technology will be aligned with Parexel’s Patient Safety Services organisation, providing a seamless transition and continuity of services to customers. During this transition period, the business will be “Vitrana–a Parexel Company,” with phased integration aligned to customer commitments and product roadmap milestones.